Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257465 · ClinicalTrials.gov registry record · Phase 1
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
A Phase 1 study of Melanoma, sponsored by AVAX Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 7
- Study locations
NCT00257465 is a Phase 1 study of Melanoma that has completed, run by AVAX Technologies. The registered enrollment target is 82 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (88% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT00257465, a Phase 1 study of Melanoma, has completed, sponsored by AVAX Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own cancer cells.
Conditions Studied
Interventions
- BIOLOGICAL Autologous, DNP-modified vaccine (M-Vax)
- BIOLOGICAL Autologous, DNP-Modified Melanoma Vaccine
- BIOLOGICAL Autologous, DNP-Modified Vaccine
Study Locations (7)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- Thomas Jefferson University - Philadelphia
Arizona
- University of Arizona Cancer Center - Tucson
California
- Pacific Oncology and Hematology Associates - San Diego
Illinois
- University of Illinois School of Medicine - Chicago
Kentucky
- University of Louisville - Louisville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257465
The ClinicalTrials.gov registry entry for NCT00257465 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (88% lower). The listed sponsor is AVAX Technologies, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Autologous, DNP-modified vaccine (M-Vax) is the first listed.
NCT00257465 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Pennsylvania, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00257465 about?
NCT00257465 is a clinical study titled "Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma". The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own cancer cells.
What is the current status of trial NCT00257465?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2005-06. Estimated completion is 2008-06.
What conditions does trial NCT00257465 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00257465?
The interventions under investigation include: Autologous, DNP-modified vaccine (M-Vax) (BIOLOGICAL), Autologous, DNP-Modified Melanoma Vaccine (BIOLOGICAL), Autologous, DNP-Modified Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00257465?
This trial is sponsored by AVAX Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00257465 being conducted?
This trial has 7 study locations across Arizona, California, Illinois, Kentucky, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.